Park Place Capital’s Viking Therapeutics VKTX Stock Holding History

Park Place Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$237	–	843
2025 Q3	$237	Hold	9	–	–	﹤0.01%	782
2025 Q2	$240	Hold	9	–	–	﹤0.01%	803
2025 Q1	$217	Buy	+9	New	+$284	﹤0.01%	817
2024 Q4	–	Sell	-9	Closed	-$570	–	876
2024 Q3	$570	Buy	+9	New	+$528	﹤0.01%	846

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Park Place Capital's VKTX Position: Q4 2025 in Review

Park Place Capital sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 9 shares — an estimated $237 sold.

Park Place Capital first reported a position in VKTX in Q3 2024 and held it in 4 quarters. The position peaked at $570 in Q3 2024. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Park Place Capital reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Park Place Capital sold 9 Viking Therapeutics shares in Q4 2025, an estimated $237.
Park Place Capital first reported a position in Viking Therapeutics in Q3 2024 and held it in 4 quarters.
Park Place Capital's Viking Therapeutics position peaked at $570 in Q3 2024.
427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Park Place Capital's 13F filing for Q4 2025, filed 9 Jan 2026.